Hutchmed (00013.HK; HCM.US) announced on September 3 that its subsidiary, Hutchison Whampoa Pharmaceutical (Shanghai), has entered into an exclusive development and licensing agreement with a subsidiary of British pharmaceutical giant GSK plc, granting the latter rights to develop and commercialize HMPL-A830 worldwide excluding mainland China, Hong Kong, Macau, and Taiwan. The total deal value could reach $1.295 billion (approximately NT$41 billion), sending Hutchmed’s Hong Kong-listed shares soaring more than 14% in afternoon trading, while its U.S. ADRs also surged over 14% in pre-market trading.

At the heart of the transaction is HMPL-A830, a first-in-class Antibody-Targeted Therapy Conjugate (ATTC) drug candidate. The drug uses a highly selective, highly potent KRAS small-molecule inhibitor as its payload, conjugated to an anti-epidermal growth factor receptor (EGFR) antibody. The antibody-guided approach enables the potent cell-killing payload to selectively concentrate in tumor tissue and exert its activity.

Clinical development will initially focus on three indications: colorectal cancer, pancreatic cancer, and lung cancer. Hutchmed noted that these three cancer types have the highest incidence of KRAS genetic alterations, and patients often lack safe and durable KRAS therapies. HMPL-A830 is designed to deliver KRAS inhibitors directly to tumors with EGFR expression, simultaneously blocking both the EGFR and KRAS signaling pathways to improve efficacy, durability, and tolerability.

Deal Structure and Development Responsibilities

Under the terms of the agreement, Hutchmed will receive a $110 million upfront payment (approximately NT$3.5 billion), along with potential development, regulatory, and commercial milestone payments totaling up to $1.295 billion, plus royalties based on net sales.

Regarding development responsibilities, Hutchison Whampoa Pharmaceutical (Shanghai) will lead the global Phase I development program for HMPL-A830, with initiation expected in the second half of 2026. GSK’s subsidiary will assume responsibility for all subsequent clinical development and commercialization activities outside mainland China, Hong Kong, Macau, and Taiwan.

ItemDetailsUpfront payment$110 millionPotential milestone paymentsUp to $1.295 billionRoyaltiesBased on net sales (rate undisclosed)Global Phase I developmentLed by Hutchison Whampoa Pharmaceutical (Shanghai)Subsequent development & commercializationGSK subsidiary (outside Greater China)Expected initiationSecond half of 2026

Note: Greater China refers to mainland China, Hong Kong, Macau, and Taiwan.

Management Commentary

Hutchmed’s Acting CEO and Chief Financial Officer Zheng Zefeng said the company shares GSK’s commitment to developing innovative cancer medicines to address significant unmet medical needs globally. He noted that HMPL-A830 is the third drug candidate from the company’s innovative payload platform, and the first candidate from the platform to be licensed to a global partner after the first two candidates entered clinical development. He believes this collaboration represents an important step for Hutchmed in maximizing the drug’s clinical potential and will open a new chapter in precision oncology treatment.

Hesham Abdullah, Senior Vice President and Global Head of Oncology R&D at GSK, said the company is committed to advancing cutting-edge innovative therapies, and that HMPL-A830’s dual KRAS-EGFR targeting mechanism has the potential to significantly improve upon current standard-of-care treatments.

Market Reaction

Following the announcement, Hutchmed’s Hong Kong-listed shares surged sharply in afternoon trading, reaching an intraday high of HK$22.3 (approximately $2.8) before closing at HK$21.82 (approximately $2.8), up 14%, with trading volume surging to 11.67 million shares worth approximately HK$250 million (approximately $31.9 million). In the U.S., Hutchmed’s American Depositary Receipts (ADRs) also jumped more than 14% in pre-market trading to $13.75.

Market observers believe the scale of the licensing deal reflects strong recognition from major international pharmaceutical companies of Hutchmed’s proprietary R&D platform. The $110 million upfront payment plus up to $1.295 billion in milestone payments represents substantial licensing terms for a mid-sized biopharmaceutical company built on independent innovation, and sets a benchmark for future international collaborations across the company’s pipeline.

Notably, this is already the third drug candidate from Hutchmed’s innovative payload platform, demonstrating the platform’s ability to consistently generate licensable assets. If HMPL-A830’s Phase I clinical data proves favorable, the probability of achieving subsequent milestone payments will increase significantly, potentially providing the company with a stable source of royalty income.